A new method to deliver drugs for Alzheimer's disease treatment.
A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures
This study is exploring a new way to deliver medications for Alzheimer's disease that could make treatments work better by targeting different aspects of the condition, so patients might have a more effective option for managing their symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Buck Institute for Research on Aging NIH-funded |
| Lab location | 1 site (Novato, United States) |
| Project ID | NIH-10873903 on NIH RePORTER |
What this research studies
This research investigates a novel smart cell drug delivery platform designed to improve the effectiveness of combination therapies for Alzheimer's disease. By focusing on multiple pathological components of the disease, including amyloid beta, tau pathology, and gliosis, the approach aims to enhance treatment outcomes. The methodology involves using a smart cell-based system that can target and regulate drug delivery, potentially overcoming the limitations of current therapies. Patients may benefit from a more effective treatment strategy that addresses the complexities of Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, particularly those in the early to moderate stages of the condition.
Not a fit: Patients with advanced Alzheimer's disease or those who do not have a confirmed diagnosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease, improving patient outcomes and quality of life.
How similar studies have performed: While combination therapies for Alzheimer's have been explored, this specific smart cell delivery approach is relatively novel and has not been widely tested in clinical settings.
Where this research is happening
Novato, United States
- Buck Institute for Research on Aging — Novato, United States (Active)
Researchers
- Principal investigator: Andersen, Julie Kay — Buck Institute for Research on Aging
- Study coordinator: Andersen, Julie Kay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.